Article

Expanded range, tints offered for progressive lenses

Roanoke, VA-The Spectacle Lens Group of Johnson & Johnson Vision Care Inc. is expanding its prescription range for the polycarbonate version of its Definity progressive lenses, and new tinted options.

Roanoke, VA-The Spectacle Lens Group of Johnson & Johnson Vision Care Inc. is expanding its prescription range for the polycarbonate version of its Definity progressive lenses, and new tinted options.

The polycarbonate lenses now are offered in +4 to -7 D in sphere range, and -0.25 to -4 D in cylinder range. They also now feature an add range of +1 to +3 D, prescribed prism range of up to +6 D, and lens diameter of 78 mm.

The Definity lenses feature "dual add" technology in which the prescription is divided over the front and back surface of the lens to reduce astigmatism and a smooth transition between distances.

The tints will be available in three densities of sunglass tints of gray, brown, and gray-green, and in cosmetic shades of light green, pink, blue, beige, yellow, violet, and more.

Lenses may be custom-tinted to match any shade, and gradient or double-gradient tinting can help reduce glare and light intensity.

Although tints do not block UV light, the company will provide an ultraviolet block free of charge on tinted Definity lenses made from CR-39. The company's GemCoat multicoating system, for anti-reflective and scratch-resistant qualities, also is available for tinted lenses.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.